Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review

• Váldodahkkit: Sirui Tan (Dahkki), Jing Yu (Dahkki), Qiyue Huang (Dahkki), Nan Zhou (Dahkki), Xianze Xiong (Dahkki), Hongfeng Gou (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2022-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Cholangiocarcinoma (CCA) is a highly aggressive malignant tumor with poor overall survival. Although the first-line standard chemotherapy (gemcitabine plus cisplatin) combined with immunotherapy has yielded positive results with survival prolongation, the efficacy remains unsatisfactory,...